Invention Application
- Patent Title: Tetrameric Cytokines with Improved Biological Activity
- Patent Title (中): 具有改善生物活性的四聚细胞因子
-
Application No.: US13219940Application Date: 2011-08-29
-
Publication No.: US20120009149A1Publication Date: 2012-01-12
- Inventor: Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
- Applicant: Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
- Applicant Address: US NJ Morris Plains
- Assignee: IBC PHARMACEUTICALS, INC.
- Current Assignee: IBC PHARMACEUTICALS, INC.
- Current Assignee Address: US NJ Morris Plains
- Main IPC: A61K38/21
- IPC: A61K38/21 ; A61K38/20 ; A61P37/02 ; A61K39/395

Abstract:
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.
Public/Granted literature
- US08597659B2 Tetrameric cytokines with improved biological activity Public/Granted day:2013-12-03
Information query
IPC分类: